Ryan Specialty posts Q2 revenue gain as E&S market slows

Ryan Specialty Holdings, Inc. reported second-quarter 2026 net commissions and fees of $902.7 million, up 7.4% year-over-year. Total revenue for the quarter reached $916.6 million, a 7.2% increase from $855.2 million a year earlier. Organic revenue growth came in at 6.7%, down from 7.1% in the prior-year period. The deceleration continues a trend across multiple quarters as the broader E&S market moderates.

Original reporting
Published Jul 31, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ryan Specialty posts Q2 revenue gain as E&S market slows — source image
Decision brief

The 30-second read

$RYANNeutralMed
01

Why it matters

Q2 growth remained positive, but organic growth decelerated and adjusted EBITDAC margin fell year over year. The company also updated full-year adjusted EBITDAC margin guidance to a further decline of 50 to 100 bps, while Empower restructuring charges are expected through 2028.

02

Market read

Traders can update expectations for Ryan Specialty’s margin trajectory and capital return pace based on the quarterly print and the revised FY margin guidance amid E&S/property softness.

03

What to watch

The Empower Program savings target ($80 million by 2029) and the expanded $300 million repurchase authorization could partially offset near-term margin pressure, but the article does not quantify timing of savings realization.

Relevance 8/10Novelty 7/10Timing: post-market reporting of Q2 results and updated FY margin guidance

Background

Ryan Specialty is an E&S insurance intermediary; the article links its deceleration to broader E&S market moderation and highlights property softness.

Company-level read

Ticker impact

$RYANNeutralMedium confidence
Context

Ryan Specialty reported Q2 2026 net commissions and fees of $902.7 million, up 7.4% YoY, while organic growth slowed to 6.7%.

Expected impact

Near-term bias likely mixed: revenue and EPS growth supportive, but margin guidance down 50 to 100 bps and property softness may cap upside.

Evidence & confidence

The article provides fresh quarterly datapoints (revenue, EBITDAC, GAAP net income) plus a guidance update for adjusted EBITDAC margin, which can drive repricing even without a surprise beat/miss narrative.

Market effects

E&S market moderation is explicitly cited, with property premiums showing the first annual decline since 2017, reinforcing sector caution.

No specific regional impact is disclosed.

No global macro or cross-border exposure details are provided.

Counterpoint

The margin decline is framed as modest (50 to 100 bps) and EPS is up 12.1%, suggesting the market may be over-discounting the restructuring impact.

Key entities

  • Ryan Specialty Holdings, Inc.

    Reported Q2 2026 financial results, updated FY 2026 adjusted EBITDAC margin guidance, and discussed Empower restructuring and capital returns.

  • Empower Program

    Three-year operational restructuring approved in February 2026 targeting $80 million annual savings by 2029, with cumulative pre-tax charges of about $160 million through 2028.

  • Patrick G. Ryan

    Founder and executive chairman quoted on organic performance and adjusted metrics.

  • Timothy W. Turner

    CEO quoted on technology, AI, data investments, and client relationships.

Related articles

$RYANMed

RYAN SPECIALTY HOLDINGS, INC. (RYAN): Results of Operations and Financial Condition

RYAN SPECIALTY HOLDINGS, INC. (RYAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ryan-20260630xex991.htm EX-99.1 RYAN-2026.06.30-EX 99.1 1 RYAN SPECIALTY REPORTS SECOND QUARTER 2026 RESULTS - Total Revenue grew 7.2% year-over-year to $916.6 million - - Organic Revenue Growth Rate* of 6.7% year-over-year - - Net Income of $108.4 million , or $0.33 pe

$KDMed

Kyndryl Q1 Earnings Call Highlights

Kyndryl (NYSE:KD) Q1 call said demand is rising for AI deployment, hybrid modernization, cybersecurity and data-residency. It reported 40 deals worth over $50M in 12 months, with 10 in Q1, and Kyndryl Consult signings up 50%. IBM relationship changes are expected to weigh on constant-currency revenue through FY2027. FCF was -$401M; cash $2.1B. Outlook FY2027 reaffirmed.

$KAIMedAI 8/10

Kadant Q2 Earnings Call Highlights

Kadant (NYSE:KAI) reported Q2 equipment backlog of $182 million and said aftermarket demand stayed at record or near-record levels. Flow Control revenue rose 5% to $100 million; Industrial Processing revenue rose to a record $144 million; Material Handling bookings were $73 million. Q2 gross margin fell to 43.8%. Kadant raised FY revenue guidance to $1.19-$1.21B and adjusted EPS to $12.43-$12.68.

$KRPMed

Kimbell Royalty Q2 Earnings Call Highlights

Kimbell Royalty (NYSE:KRP) reported record Q2 adjusted EBITDA of $84.9 million, with cash G&A of $5.9 million ($2.50 per BOE). It declared a $0.47 per common unit cash distribution, up 15% QoQ, and said 47% may be return of capital. The borrowing base rose to $660 million; debt was $478.7 million. Rig activity and production varied by basin.